TYRX's first commercially available product is the AIGISRx Antibacterial Envelope for cardiac implantable electronic devices (CIEDs).
The AIGISRx is intended to securely hold a pacemaker or defibrillator in place to create a stable environment.
More information can be found at AIGISRx Antibacterial Envelope.
News & Events
Vanderbilt Study Shows 87% Decline in CIED Infections with AIGISRx® Antibacterial Envelope
• Study of patients at high risk for CIED infection published in journal of Pacing and Electrophisiology (PACE), March 2013.
• Results show 0.4% CIED infection rate in patients who received AIGISRx implants, compared to 3.0% in control group that did not receive AIGISRx implants (p=0.04)
See Attached Link:
TYRX Press Release